De Regil, World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults, JAMA , Dec
The same medications can also create practical side-effect questions
Semaglutide 2.4 mg (Wegovy, FDA-approved for weight management) reports diarrhea in approximately 30% of patients in clinical trials according to the FDA prescribing information
Why the GutMetabolism Connection Matters
The program helps you to: Gain Confidence With GLP-1 & Related Therapies: Understand GLP-1 mechanisms, indications, benefits, and risks to design nutrition plans that preserve lean mass and support overall treatment outcomes
New Indications : GLP-1 drugs are being tested for obesity-related conditions (NASH/non-alcoholic steatohepatitis, cardiovascular risk reduction, etc.)